Bio <-> Chem: Back-story on Novartis LCZ696 database links
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure | NEJM
Heart failure with preserved ejection fraction: emerging drug strategies. - Abstract - Europe PMC
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Sacubitril/valsartan - Wikipedia
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM
sacubitril | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Sacubitril - Wikipedia
Neprilysin - Wikipedia
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
VALSARTAN
Sacubitril | New Drug Approvals
Bio <-> Chem: Back-story on Novartis LCZ696 database links
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Frontiers | Neprilysin Inhibitors and Bradykinin
SACUBITRIL
Sacubitril – Wikipedia
Frontiers | Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Olmesartan | C24H26N6O3 | CID 158781 - PubChem
Entresto | C96H120N12Na6O21 | CID 71449007 - PubChem
Is Entresto good for the brain? - Abstract - Europe PMC
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
